At TCT 2025, Professor Wang Yan from Xiamen Cardiovascular Hospital was invited to deliver a keynote report titled "First-in-Human Robotic-Assisted TAVR for the Treatment of Severe Aortic Valve Stenosis," presenting to global peers for the results of world's first robot-assisted TAVR EFS trial of China's original ReachTactile® robot-assisted transcatheter aortic valve replacement procedure.

Professor Wang presented clinical data from five completed robot- assisted TAVR procedures at the hospital: the patient group had an average age of 72.4 years, all with severe aortic stenosis. The immediate technical success rate was 100%, with an average procedure time of 15 minutes for the complete TAVR system from entry to withdrawal. All five patients have completed 30-day follow-up with no major adverse cardiovascular or cerebrovascular events, and the hemodynamic performance of the prosthetic valves met therapeutic expectations without delayed complications.